BeOne Medicines Ltd. (ONC) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ONC Revenue Growth
Revenue Breakdown (FY 2025)
ONC's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ONC Revenue Analysis (2014–2025)
As of May 8, 2026, BeOne Medicines Ltd. (ONC) generated trailing twelve-month (TTM) revenue of $5.74 billion, reflecting explosive growth of +35.5% year-over-year. The most recent quarter (Q1 2026) recorded $1.51 billion in revenue, up 1.0% sequentially.
Looking at the longer-term picture, ONC's 5-year compound annual growth rate (CAGR) stands at +76.8%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $5.34 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows ONC's business is primarily driven by Product (99%), and Collaboration (1%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ZYME (-15.6% YoY), RCUS (+67.4% YoY), and TGTX (+81.3% YoY), ONC has underperformed the peer group in terms of revenue growth. Compare ONC vs ZYME →
ONC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ONCCurrent | $5.7B | +35.5% | +76.8% | 8.4% | |
 ZYME | $106M | -15.6% | +22.2% | -87.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 MGNX | $150M | +0.8% | +8.9% | -48.7% |
ONC Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5.34B | +40.2% | $4.67B | 87.5% | $447.1M | 8.4% |
| 2024 | $3.81B | +55.0% | $3.22B | 84.4% | $-568,199,000 | -14.9% |
| 2023 | $2.46B | +73.7% | $2.08B | 84.5% | $-1,207,736,000 | -49.1% |
| 2022 | $1.42B | +20.4% | $1.13B | 79.8% | $-1,789,665,000 | -126.4% |
| 2021 | $1.18B | +280.8% | $1.01B | 86.0% | $-1,438,735,000 | -122.3% |
| 2020 | $308.9M | -27.9% | $238.2M | 77.1% | $-1,657,682,000 | -536.7% |
| 2019 | $428.2M | +116.0% | $357.0M | 83.4% | $-959,891,000 | -224.2% |
| 2018 | $198.2M | -16.8% | $-509,490,000 | -257.0% | $-705,769,000 | -356.1% |
| 2017 | $238.4M | +22179.2% | $-35,605,000 | -14.9% | $-98,457,000 | -41.3% |
| 2016 | $1.1M | -87.9% | $-96,963,000 | -9062.0% | $-117,060,000 | -10940.2% |
Full ONC Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ONC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ONC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ONC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonONC — Frequently Asked Questions
Quick answers to the most common questions about buying ONC stock.
Is ONC's revenue growth accelerating or slowing?
ONC revenue is accelerating at +35.5% year-over-year, exceeding the 5-year CAGR of +76.8%. TTM revenue reached $5.7B. Growth momentum has increased versus prior periods.
What is ONC's long-term revenue growth rate?
BeOne Medicines Ltd.'s 5-year revenue CAGR of +76.8% reflects the sustained expansion pattern. Current YoY growth of +35.5% is above this long-term average.
How is ONC's revenue distributed by segment?
ONC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.